Imaging Study in Metastatic Clear Cell RCC.
A Phase 0 Imaging Study to Assess the Feasibility, Biodistribution, and Dosimetry of the Imaging Agent in Subjects With Metastatic Clear Cell Renal Cell Cancer (RCC).
- Metastatic Clear Cell Renal Cell Carcinoma
At a glance
- Phase
- Early phase 1
- Study type
- Interventional
- Sponsor
- RayzeBio, Inc.
- Enrolment target
- 10
- Started
- 15 June 2026
- Main results due
- January 2027
- Study sites
- 4
- Registry updated
- 29 September 2026
Can you take part?
- Aged 18 years and over.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: * At least 18 years old at the time of signing the informed consent form (ICF). * Biopsy proven metastatic clear cell renal cell carcinoma (RCC) Exclusion Criteria: * Subjects taking below mentioned medications that cannot be stopped 5 half-lives prior to RYZ512 administration and cannot be restarted until all study-related imaging is completed: Anticonvulsants, Antipsychotics, Carbonic Anhydrase inhibitors, COX-2 Inhibitors, Sulfatase Inhibitors, Sulfonamides * Women of Childbearing Potential that are pregnant or breastfeeding. Note: Additional criteria may apply and will be assessed by the study site
What this study is about
In the sponsor’s own words, from the registry.
This imaging study aims to assess the feasibility, biodistribution, and dosimetry of the imaging agent in Subjects with Metastatic Clear Cell Renal Cell Cancer (RCC).
Study sites(4)
Research Facility
Saint Leonards, New South Wales, Australia
Recruiting
Research Facility
Nedlands, Australia
Recruiting
Research Facility
Perth, Australia
Recruiting
Research Facility
Christchurch, New Zealand
Recruiting
Showing 4 of 4 sites. 4 of the 4 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT07671417. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me